Sign up to save your podcasts
Or
Share ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
ASGCT, Adcomm for Lilly’s Donanemab, Vertex Vs. Bluebird
In this edition of The Weekly, Managing Editor
Jef Akst and News Editor Greg Slabodkin share their insights from the American Society of Gene
& Cell Therapy’s 27th annual conference, including advances around adeno-associated viruses and the
ongoing discussion about the FDA’s accelerated approval program and how it relates to rare diseases.
Also, on Tuesday, Eli Lilly announced that an advisory committee meeting will be held for its Alzheimer’s drug donanemab on June 10. Lilly is aiming for full approval of the anti-amyloid antibody after accelerated approval was denied in January 2023. And the race between Vertex and bluebird bio’s gene therapies Casgevy and Lyfgenia is heating up.
View all episodes
By BioSpace
4.9
1313 ratings
In this edition of The Weekly, Managing Editor
Jef Akst and News Editor Greg Slabodkin share their insights from the American Society of Gene
& Cell Therapy’s 27th annual conference, including advances around adeno-associated viruses and the
ongoing discussion about the FDA’s accelerated approval program and how it relates to rare diseases.
Also, on Tuesday, Eli Lilly announced that an advisory committee meeting will be held for its Alzheimer’s drug donanemab on June 10. Lilly is aiming for full approval of the anti-amyloid antibody after accelerated approval was denied in January 2023. And the race between Vertex and bluebird bio’s gene therapies Casgevy and Lyfgenia is heating up.
More shows like BioSpace
View all
This American Life
90,994 Listeners
Planet Money
30,666 Listeners
Hidden Brain
43,528 Listeners
Marketplace
8,776 Listeners
Exchanges
970 Listeners
WSJ What’s News
4,345 Listeners
Bloomberg Surveillance
1,170 Listeners
Odd Lots
1,967 Listeners
Up First from NPR
56,508 Listeners
The Indicator from Planet Money
9,532 Listeners
The Readout Loud
337 Listeners
The Journal.
6,089 Listeners
Short Wave
6,564 Listeners
BioCentury This Week
34 Listeners
Biotech Hangout
23 Listeners